Search results for "TRANSTHYRETIN AMYLOIDOSIS"

showing 2 items of 2 documents

Valorization of apple peels through the study of the effects on the amyloid aggregation process of ?-casein

2021

Waste valorization represents one of the main social challenges when promoting a circular economy and environmental sustainability. Here, we evaluated the effect of the polyphenols extracted from apple peels, normally disposed of as waste, on the amyloid aggregation process of ?-casein from bovine milk, a well-used amyloidogenic model system. The effect of the apple peel extract on protein aggregation was examined using a thioflavin T fluorescence assay, Congo red binding assay, circular dichroism, light scattering, and atomic force microscopy. We found that the phenolic extract from the peel of apples of the cultivar "Fuji", cultivated in Sicily (Caltavuturo, Italy), inhibited ?-casein fib…

Circular dichroismMalusAmyloidAmyloidSettore CHIM/10 - Chimica Degli Alimenti&#954INHIBITIONPharmaceutical ScienceOrganic chemistryPROTEINProtein aggregationMicroscopy Atomic ForceFIBRIL FORMATIONArticleAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineQD241-441OLIGOMERSCaseinTRANSTHYRETIN AMYLOIDOSISANTIOXIDANTDrug Discovery-casein amyloid aggregationFood sciencePhysical and Theoretical Chemistrypolyphenolic extract030304 developmental biology0303 health sciencesbiologyChemistryNATURAL POLYPHENOLSCaseinsκ-casein amyloid aggregationbiology.organism_classificationSTATECongo redfruit wasteChemistry (miscellaneous)PolyphenolFIBRILLOGENESISMalusFruit waste; Polyphenolic extract; ?-casein amyloid aggregationMolecular MedicineThioflavinTHIOFLAVIN-T030217 neurology & neurosurgery
researchProduct

Use of drugs for attrv amyloidosis in the real world: How therapy is changing survival in a non-endemic area

2021

Background: Over the past decade, three new drugs have been approved for the treatment of hereditary amyloid transthyretin (ATTRv) polyneuropathy. The aim of this work was to analyze whether current therapies prolong survival for patients affected by ATTRv amyloidosis. Methods: The study was conducted retrospectively, analyzing the medical records of 105 patients with genetic diagnoses of familial amyloidotic polyneuropathy followed at the two referral centers for the disease in Sicily, Italy. Of these, 71 received disease-modifying therapy, while 34 received only symptomatic treatment or no therapy. Results: The most used treatment in our patient cohort was tafamidis, followed by liver tra…

Tafamidismedicine.medical_specialtySurvivalmedicine.medical_treatmentHereditary transthyretin amyloidosisNeurosciences. Biological psychiatry. NeuropsychiatryDisease030204 cardiovascular system & hematologyLiver transplantationArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNon-V30MInternal medicineATTRvPolyneuropathyMedicineATTRv; hereditary transthyretin amyloidosis; inotersen; non-V30M; patisiran; polyneuropathy; survival; tafamidis; patisiran; inotersenbiologybusiness.industryGeneral NeuroscienceAmyloidosisMedical recordmedicine.diseaseTafamidisTransthyretinchemistryCohortbiology.proteinPatisiranSettore MED/26 - NeurologiabusinessPolyneuropathy030217 neurology & neurosurgeryRC321-571Inotersen
researchProduct